Joshi M G, Lee A K, Loda M, Camus M G, Pedersen C, Heatley G J, Hughes K S
Department of Anatomic Pathology, Lahey Hitchcock Medical Center, Burlington, Massachusetts 01805, USA.
Cancer. 1996 Feb 1;77(3):490-8. doi: 10.1002/(SICI)1097-0142(19960201)77:3<490::AID-CNCR10>3.0.CO;2-#.
Although breast cancer in men is far less common than breast cancer in women, it is associated with a less favorable prognosis. Conventional histopathologic features and new prognostic markers were evaluated to explain the less favorable survival outcome.
Forty-six consecutive male breast carcinomas were studied for size, histologic and nuclear grade, histologic subtype, presence of carcinoma in situ, nipple involvement, lymphovascular invasion, hormone receptor status, c-erbB-2 protein overexpression, and p53 protein accumulation. These findings were correlated with survival.
Of the 46 carcinomas, 4 were noninvasive and 42 were invasive. In the invasive carcinomas, the median patient age was 64 years, and the median tumor size was 2 cm. The predominant histologic patterns were invasive ductal (45%) and mixed invasive ductal and cribriform (28%). Most tumors were of low histologic and nuclear grades (histologic grades: I, 17%; II, 50%; III, 33%; nuclear grade: I, 12%; II, 44%; III, 44%). Of those surgically staged, 22 patients (60%) were lymph node positive and 15 patients (40%) were node negative. Stage at presentation was higher than in women (0, 10%; 1, 17%; 2, 50%; 3, 13%; 4, 10%). The estrogen and progesterone receptor status was positive in 76% and 83% of tumors, respectively. Lymphatic vessel invasion (63%) and nipple involvement (48%) were also more common than in women. True Paget's disease of the nipple was not seen; all cases with nipple ulceration were the result of direct tumor extension to the epidermis. Of the 17 tumors tested, 41% were c-erbB-2 positive and 29% were p53 positive. Survival analysis was limited by the relatively small cohort size. Five- and 10-year adjusted overall survival rates for invasive tumors were 76 +/- 7% and 42 +/- 9%, respectively. Skin and nipple involvement (P = 0.03) and c-erbB-2-positivity (P = 0.03) were significant predictors of adverse survival.
Male breast carcinoma presents in an advanced stage with less favorable survival, despite low histologic grade, high estrogen receptor content, and small size. Anatomic factors may have been responsible for the poor survival outcome (i.e., paucity of breast tissue and close tumor proximity to skin and nipple, facilitating dermal lymphatic spread and early regional and distant metastasis).
尽管男性乳腺癌远比女性乳腺癌少见,但其预后较差。对传统组织病理学特征和新的预后标志物进行评估,以解释其较差的生存结局。
对46例连续性男性乳腺癌患者的肿瘤大小、组织学和核分级、组织学亚型、原位癌的存在、乳头受累情况、淋巴管侵犯、激素受体状态、c-erbB-2蛋白过表达及p53蛋白积聚情况进行研究。将这些结果与生存情况进行关联分析。
46例癌中,4例为非浸润性,42例为浸润性。浸润性癌患者的中位年龄为64岁,中位肿瘤大小为2cm。主要组织学类型为浸润性导管癌(45%)和浸润性导管癌与筛状癌混合类型(28%)。大多数肿瘤的组织学和核分级较低(组织学分级:I级,17%;II级,50%;III级,33%;核分级:I级,12%;II级,44%;III级,44%)。在接受手术分期的患者中,22例(60%)有淋巴结转移,15例(40%)无淋巴结转移。初诊时的分期高于女性患者(0期,10%;1期,17%;2期,50%;3期,13%;4期,10%)。雌激素和孕激素受体状态阳性的肿瘤分别占76%和83%。淋巴管侵犯(63%)和乳头受累(48%)也比女性患者更常见。未发现真正的乳头佩吉特病;所有乳头溃疡病例均为肿瘤直接蔓延至表皮所致。在检测的17例肿瘤中,41%的肿瘤c-erbB-2阳性,29%的肿瘤p53阳性。生存分析因队列规模相对较小而受到限制。浸润性肿瘤的5年和10年校正总生存率分别为76±7%和42±9%。皮肤和乳头受累(P = 0.03)及c-erbB-2阳性(P = 0.03)是生存不良的显著预测因素。
男性乳腺癌初诊时分期较晚,生存较差,尽管其组织学分级低、雌激素受体含量高且肿瘤较小。解剖学因素可能是导致生存不良结局的原因(即乳腺组织较少以及肿瘤与皮肤和乳头距离较近,有利于真皮淋巴管扩散及早期区域和远处转移)。